Ksizal Tablets p / o 5 mg, # 10

Ksizal tab.

p / o captivity.

5mg No. 10

Name ENG

XYZAL

Clinical and pharmacological group

Blocker of histamine H1 receptors.

Antiallergic drug

ATX code

Levocetirizine

Dosage

5mg

Structure

1 tablet contains 5 mg levocetirizine dihydrochloride.

Indications

For adults and children over 6 years of age: treatment of symptoms of perennial and seasonal allergic rhinitis and allergic conjunctivitis, such as itching, sneezing, lacrimation, conjunctival hyperemia

hay fever (hay fever)

urticaria, including chronic idiopathic urticaria, Quincke's edema

other allergic dermatoses, accompanied by itching and rashes.

Contraindications

Hypersensitivity to any component of the drug or piperazine derivatives.

Severe chronic renal failure (creatinine clearance less than 10 ml / min).

Children's age (up to 6 years old).

With caution - chronic renal failure (correction of the dosage regimen is required), old age (a decrease in glomerular filtration is possible).

Storage conditions and periods

In a dry place, at a temperature not exceeding 25 degrees.

Expiration date: 4 years

INN / Active ingredient

Levocetirizine

Specifications

Category

Allergy

Scope of the drug

Metabolism

Release form

Tablet

Manufacturer country

Switzerland

Package quantity, pcs

ten

Scope of application

Allergology

Minimum age from

6 years

Way of introduction

Through the mouth

Vacation conditions

Without recipe

Brand name

UCB

The amount of the dosage form in the primary package

10 pieces.

Primary packaging type

Blister

Type of consumer packaging

Pack of cardboard

Anatomical and therapeutic characteristics

R06AE09 Levocetirizine

Dosage form

Film-coated tablets

Packaging

Box

Dosage (volume) of the substance in the preparation

1 ml: levocetirizine dihydrochloride 5 mg

Expiration date in days

1460

The target audience

Children

Package weight, g

15

Mode of application

:

It is taken orally with food or on an empty stomach, with a small amount of water without chewing.

Adults and children over 6 years old: daily dose - 5 mg (1 tablet).

Elderly patients (subject to normal renal function) dose reduction is not required.

For patients with chronic renal failure, the dose is reduced by half (1 tablet every other day) with CC from 30 to 49 ml / min and 3 times (1 tablet every 3 days) with CC from 10 to 29 ml / min.

Patients with hepatic insufficiency do not need to correct the dosage regimen. < br> < br> The duration of admission depends on the disease.

For the treatment of pollinosis, it is prescribed on average for 1-6 weeks.

In chronic diseases (perennial rhinitis, atonic dermatitis), the duration of treatment may increase to 18 months. < br> < br>

Pharmaco-therapeutic group

:

Antiallergic agent - H1-histamine receptor blocker